1. Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. (December 2021) Authors: Bartoletti, M.; Musacchio, L.; Giannone, G.; Tuninetti, V.; Bergamini, A.; Scambia, G.; Lorusso, D.; Valabrega, G.; Mangili, G.; Puglisi, F.; Pignata, S. Journal: Cancer treatment reviews Issue: Volume 101(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. (May 2021) Authors: Ghisoni, E.; Wicky, A.; Bouchaab, H.; Imbimbo, M.; Delyon, J.; Gautron Moura, B.; Gérard, C.L.; Latifyan, S.; Özdemir, B.C.; Caikovski, M.; Pradervand, S.; Tavazzi, E.; Gatta, R.; Marandino, L.; Valabrega, G.; Aglietta, M.; Obeid, M.; Homicsko, K.; Mederos Alfonso, N.N.; Zimmermann, S. Journal: European journal of cancer Issue: Volume 149(2021) Page Start: 153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series. (April 2018) Authors: Giannone, G.; Milani, A.; Ghisoni, E.; Genta, S.; Mittica, G.; Montemurro, F.; Valabrega, G. Journal: Breast Issue: Volume 38(2018) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗